Cédric Duval1, Majid Ali1, Waleed W Chaudhry1, Victoria C Ridger1, Robert A S Ariëns2, Helen Philippou1. 1. From the Thrombosis and Tissue Repair Group, Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular And Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom (C.D., M.A., W.W.C., R.A.S.A., H.P.); and Department of Cardiovascular Science, Faculty of Medicine, Dentistry, and Health, University of Sheffield, Sheffield, South Yorkshire, United Kingdom (V.C.R.). 2. From the Thrombosis and Tissue Repair Group, Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular And Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom (C.D., M.A., W.W.C., R.A.S.A., H.P.); and Department of Cardiovascular Science, Faculty of Medicine, Dentistry, and Health, University of Sheffield, Sheffield, South Yorkshire, United Kingdom (V.C.R.). R.A.S.Ariens@leeds.ac.uk.
Abstract
OBJECTIVE: Factor XIII (FXIII) cross-links fibrin upon activation by thrombin. Activation involves cleavage at residue 37 by thrombin, releasing an activation peptide. A common polymorphism (valine to leucine variant at residue 34, V34L), located in the activation peptide, has been associated with increased activation rates and paradoxically a protective effect in cardiovascular disease. There is, currently, no data available on the effects of V34L from in vivo models of thrombosis. We examined the effect of FXIII V34L on clot formation and cross-linking in vivo. APPROACH AND RESULTS: We generated a panel of full-length recombinant human FXIII-A2 variants with amino acid substitutions in the activation peptide to investigate the effect of these variants on activation rate, and we used wild-type, V34L, and alanine to glycine variant at residue 33 variants to study the effects of varying FXIII activation rate on thrombus formation in a murine model of FeCl3 injury. FXIII activation assay showed that residues 29, 30, 33, and 34 play a critical role in thrombin interaction. Full-length recombinant human FXIII-A2 V34L has significant effects on clot formation, structure, and lysis in vitro, using turbidity assay. This variant influenced fibrin cross-linking but not size of the thrombus in vivo. CONCLUSIONS: Mutations in the activation peptide of full-length recombinant FXIII regulate activation rates by thrombin, and V34L influences in vivo thrombus formation by increased cross-linking of the clot.
OBJECTIVE: Factor XIII (FXIII) cross-links fibrin upon activation by thrombin. Activation involves cleavage at residue 37 by thrombin, releasing an activation peptide. A common polymorphism (valine to leucine variant at residue 34, V34L), located in the activation peptide, has been associated with increased activation rates and paradoxically a protective effect in cardiovascular disease. There is, currently, no data available on the effects of V34L from in vivo models of thrombosis. We examined the effect of FXIII V34L on clot formation and cross-linking in vivo. APPROACH AND RESULTS: We generated a panel of full-length recombinant human FXIII-A2 variants with amino acid substitutions in the activation peptide to investigate the effect of these variants on activation rate, and we used wild-type, V34L, and alanine to glycine variant at residue 33 variants to study the effects of varying FXIII activation rate on thrombus formation in a murine model of FeCl3 injury. FXIII activation assay showed that residues 29, 30, 33, and 34 play a critical role in thrombin interaction. Full-length recombinant human FXIII-A2 V34L has significant effects on clot formation, structure, and lysis in vitro, using turbidity assay. This variant influenced fibrin cross-linking but not size of the thrombus in vivo. CONCLUSIONS: Mutations in the activation peptide of full-length recombinant FXIII regulate activation rates by thrombin, and V34L influences in vivo thrombus formation by increased cross-linking of the clot.
Authors: Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer Journal: FEBS J Date: 2019-08-28 Impact factor: 5.542
Authors: Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer Journal: Biochim Biophys Acta Proteins Proteom Date: 2017-07-04 Impact factor: 3.036
Authors: Sravya Kattula; Yaqiu Sang; Gustaaf de Ridder; Anna C Silver; Emma G Bouck; Brian C Cooley; Alisa S Wolberg Journal: J Thromb Haemost Date: 2021-09-06 Impact factor: 5.824
Authors: Nathan L Asquith; Cédric Duval; Artem Zhmurov; Stephen R Baker; Helen R McPherson; Marco M Domingues; Simon D A Connell; Valeri Barsegov; Robert A S Ariëns Journal: Blood Adv Date: 2022-07-12
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Cédric Duval; Adomas Baranauskas; Tímea Feller; Majid Ali; Lih T Cheah; Nadira Y Yuldasheva; Stephen R Baker; Helen R McPherson; Zaher Raslan; Marc A Bailey; Richard M Cubbon; Simon D Connell; Ramzi A Ajjan; Helen Philippou; Khalid M Naseem; Victoria C Ridger; Robert A S Ariëns Journal: Proc Natl Acad Sci U S A Date: 2021-07-06 Impact factor: 11.205